DZS Clinical Services announced today that SBI Pharmaceuticals, the leading expert in research, development, and manufacturing of 5-ALA, has entered into a preferred provider agreement with DZS to manage several clinical programs related to the development of 5-ALA.
Bound Brook, NJ (PRWEB) July 24, 2014
As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion.
“We are delighted to have a preferred provider agreement with DZS to manage our clinical trials globally and in particular in the MENA region,” said Global VP of R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh Rehani. “DZS has developed excellent operational practices with a focus on utilizing eClinical software and flexible team structures that allow companies to reduce development costs yet maintain high quality services and meet timelines. This helps pharma companies to meet the many challenges of drug development.”
“We are pleased to be able to partner with SBI at a strategic level. Our Sponsors are increasingly looking for innovative approaches to bring products to market effectively and efficiently,” said Greg Ambra, VP of Clinical Operations. “Our flexible project team models, collaborative approach, and proprietary eClinical Software, ClinPlus®, increases the level of collaboration and allows us to respond quickly to our Sponsor’s needs, while maintaining our focus on high quality deliverables.”
About DZS Clinical Services:
DZS Clinical Services is a full-service Contract Research Organization providing clinical trial services and eClinical software for the biotech and pharmaceutical industry. DZS Clinical Services is a division of DZS Software Solutions, Inc., a privately held company founded in 1984. Over 60 clients globally use DZS services and software for trial monitoring and management, data capture, data cleaning, analysis, and reporting. When ClinPlus® software is coupled with DZS services and training, clients have dramatically improved productivity and maximized the value of R&D investments by obtaining fast, high-quality results leading to better decisions.